News -

Discover new iLite™ IL-23 Assay Ready Cells

We are happy to introduce the iLite™ IL-23 Assay Ready Cells offering significant benefits as compared to conventional IL-23 assays. Using the iLiteIL-23 Assay Ready Cells, a rapid assay for the functional activity of IL-23, without cross-reactivity with IL-12, can easily be set-up. Results are obtained within 6 h.

Euro Diagnostica is now strengthening the iLite™ portfolio within inflammation by adding iLite™ IL-23 Assay Ready Cells to the portfolio. This highly specific reporter gene cell line can be used for quantifying IL-23 activity, IL-23 inhibitor activity, e.g. Ustekinumab, and the activity of neutralizing antibodies against the latter.

IL-23 is a pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. IL-23 has been implicated as an inflammation mediator in several autoimmune diseases, and therapeutic agents targeting both IL-23 and IL-12 cytokines are currently used to treat psoriasis and psoriatic arthritis. In addition, related agents are in clinical testing for a variety of inflammatory disorders.

As all iLite™cell lines the IL-23 Assay Ready Cells are delivered frozen and used directly from the freezer without any need for cultivation allowing for a rapid, easy and simple test format. The assay deliver quantitative results within 6 hours.

For more information, please see the iLite™ product page.

We are continuously releasing new iLite™cell lines - make sure to stay tuned for the coming launch of the highly related product iLite™ IL-12 Assay Ready Cells.

Related links

Topics

  • Diseases

Categories

  • product
  • ilite cell-based assays

Contacts

Related content

  • Announcing the launch of iLite™ VEGF Assay Ready Cells

    The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

  • New research on cell-based reporter gene iLite™ assays

    The 10th International Congress on Autoimmunity is taking place in Leipzig, Germany April 6-10. The event provides an opportunity to hear about the hot topics in autoimmunity and discuss the newest therapeutic techniques and diagnostic tools as well as the most up-to-date research. We are happy to announce that we will hold a presentation relating to the use of a cell-based reporter gene assay.

Related events